Use of Micro-RNA as a Biomarker of Immunomodulatory Drug Activity
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/US2016/043511, filed Jul 22, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 7,964,354 | Use of Micro-RNA as a Biomarker of Immunomodulatory Drug Activity In force · High confidence | Celgene Corporation | In force | High confidence | ||
| US 10,252,981 | Methods of Synthesis of (1R,2R,5R)-5-Amino-2-Methylcyclohexanol Hydrochloride and Intermediates Useful Therein In force · High confidence | Celgene Corporation | In force | High confidence | ||
| US 10,774,033 | Methods of Synthesis of (1R,2R,5R)-5-Amino-2-Methylcyclohexanol Hydrochloride and Intermediates Useful Therein In force · Medium confidence | Celgene Corporation | In force | Medium confidence | ||
| US 11,192,847 | Methods of Synthesis of (1R,2R,5R)-5-Amino-2-Methylcyclohexanol Hydrochloride and Intermediates Useful Therein In force · Medium confidence | Celgene Corporation | In force | Medium confidence | ||
| US 11,780,801 | Methods of Synthesis of (1R,2R,5R)-5-Amino-2-Methyl-CYCLOHEXANOL Hydrochloride and Intermediates Useful Therein In force · Medium confidence | Celgene Corporation | In force | Medium confidence | ||
| US 10,428,145 | PD-1 Binding Proteins and Methods of Use Thereof In force · High confidence | Celgene Corporation | In force | High confidence | ||
| US 10,766,958 | Methods of Treating Vitiligo Using PD-1 Binding Antibodies In force · High confidence | Celgene Corporation | In force | High confidence | ||
| US 10,751,414 | Methods of Treating Psoriasis Using PD-1 Binding Antibodies In force · High confidence | Celgene Corporation | In force | High confidence | ||
| US 11,096,940 | Treatment of Hepatocellular Carcinoma Characterized by Hepatitis B Virus Infection In force · High confidence | Celgene Corporation | In force | High confidence | ||
| US 10,357,489 | Antiproliferative Compounds and Methods of Use Thereof In force · High confidence | Celgene Corporation | In force | High confidence | ||
| 35 more patents in this group · Pro | ||||||
10 of 45 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 45.
29 of these are in force and held by Celgene Corporation.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.